Paper Details

  1. Home
  2. Paper Details

Cost-effectiveness analysis of the early conversion of tacrolimus to mammalian target of rapamycin inhibitors in patients with renal transplantation.

Author: BenavidesC, CastilloJ S, GamboaO, MesaL, MonteroC, ReinoA, TorresR E

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Kidney transplantation and dialysis are the only treatments for people with end-stage kidney failure. These treatments have transformed this once fatal condition into a manageable chronic illness. Kidney transplant patients require medications to suppress the immune system and prevent rejection. Several medications are available, each with varying effectiveness, safety, and costs.
Paper Details　
Original Abstract of the Article :
Renal replacement therapies which consist of renal transplantation and dialysis are the only treatment options for patients with terminal renal failure. These therapies have changed the outcome from being fatal to being a chronic disease. Kidney transplantation involves the use of immunosuppressive ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.transproceed.2011.09.092

データ提供：米国国立医学図書館（NLM）

Early conversion of tacrolimus to mTOR inhibitors: A cost-effective strategy for renal transplantation

This research delves into the complex world of renal transplantation, exploring the cost-effectiveness of early conversion from tacrolimus to mammalian target of rapamycin (mTOR) inhibitors. The study, analyzing the financial implications of this treatment strategy, suggests that early conversion to mTOR inhibitors can be a cost-effective approach for patients undergoing renal transplantation. This research provides valuable insights into the economic considerations involved in renal transplantation, guiding clinicians in optimizing treatment strategies while minimizing costs.

Balancing effectiveness and cost: A strategic approach to renal transplantation

The study's findings highlight the importance of considering both clinical effectiveness and cost-effectiveness in managing renal transplantation. The research suggests that early conversion to mTOR inhibitors can be a viable option, balancing therapeutic benefits with financial considerations. This research underscores the need for a strategic approach to renal transplantation, optimizing treatment strategies while minimizing costs and maximizing long-term outcomes for patients.

Navigating the financial landscape of transplantation: A collaborative effort

This research emphasizes the importance of collaborative efforts between healthcare professionals, patients, and policymakers in managing the costs associated with renal transplantation. By considering cost-effective treatment strategies and exploring innovative approaches to reduce financial burden, we can ensure access to high-quality transplantation care for all individuals in need. This research highlights the value of a multi-faceted approach to addressing the financial challenges of transplantation, working together to optimize outcomes and ensure equitable access to this life-saving procedure.

Dr. Camel's Conclusion

This research delves into the cost-effectiveness of early conversion from tacrolimus to mTOR inhibitors in renal transplantation. The study's findings suggest that this strategy can be a viable option, balancing therapeutic benefits with financial considerations. This research underscores the need for a strategic approach to renal transplantation, optimizing treatment strategies while minimizing costs and maximizing long-term outcomes for patients.

Date :
  1. Date Completed 2014-09-30
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

22099798

DOI: Digital Object Identifier

10.1016/j.transproceed.2011.09.092

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.